Innohep

Deep Vein Thrombosis (DVT), prophylaxis of Clotting, Thrombosis + 6 more
Treatment
13 FDA approvals
20 Active Studies for Innohep

What is Innohep

TinzaparinThe Generic name of this drug
Treatment SummaryTinzaparin is an anticoagulant and antithrombotic drug used to prevent clotting. It is produced by breaking down a more complex form of heparin, a natural substance found in the intestines of pigs. Tinzaparin binds to a protein called antithrombin III to stop the action of a certain enzyme called factor Xa. It is a low molecular weight heparin, meaning it is shorter than other types of heparin and is less effective at stopping the action of factor IIa. Tinzaparin must be injected into the muscle or under the skin.
Innohepis the brand name
image of different drug pills on a surface
Innohep Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Innohep
Tinzaparin
2008
2

Approved as Treatment by the FDA

Tinzaparin, otherwise known as Innohep, is approved by the FDA for 13 uses including Clotting and Deep Vein Thrombosis .
Clotting
Deep Vein Thrombosis
Used to treat Deep Vein Thrombosis in combination with Warfarin
Venous Thromboembolism
Pulmonary embolism, Deep vein thrombosis
Used to treat Pulmonary embolism, Deep vein thrombosis in combination with Warfarin
Deep Vein Thrombosis (DVT)
Deep Vein Thrombosis
Used to treat Deep Vein Thrombosis in combination with Warfarin
Orthopedic Procedures
Prophylaxis of Venous Thromboembolic Events
indwelling intravenous lines
Pulmonary Embolism
Used to treat Pulmonary embolism, Deep vein thrombosis in combination with Warfarin
Thrombosis
prophylaxis of Clotting
General Surgery

Effectiveness

How Innohep Affects PatientsTinzaparin is an anticoagulant that works by blocking the formation of blood clots. It is different from heparin, as it has higher activity against Factor Xa than Factor IIa. Routine monitoring of tinzaparin levels is not recommended. However, it may be monitored in certain cases, such as pregnancy or renal dysfunction. Tinzaparin should not be used in patients with a creatinine clearance below 20 mL/min, as it can cause serious side effects. However, it can be safely used in those with a creatinine clearance between 20-30 mL/min, making
How Innohep works in the bodyTinzaparin works by preventing the formation of a clot. It does this by binding to a protein in the blood called antithrombin III and forming a complex with it. This complex accelerates the inhibition of factor Xa, which stops the production of thrombin. Without thrombin, fibrinogen cannot be converted to fibrin, which is needed to form clots. Tinzaparin must be given intravenously due to the increased risk of hematoma if injected intramuscularly.

When to interrupt dosage

The advised dosage of Innohep is contingent upon the diagnosed affliction, including prophylaxis of Clotting, Pulmonary Embolism and Deep Vein Thrombosis. The measure of dosage fluctuates as per the administration approach outlined in the table below.
Condition
Dosage
Administration
Deep Vein Thrombosis (DVT)
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
prophylaxis of Clotting
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
Thrombosis
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
Pulmonary Embolism
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
indwelling intravenous lines
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
Deep Vein Thrombosis
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
Orthopedic Procedures
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
Prophylaxis of Venous Thromboembolic Events
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous
General Surgery
20000.0 [iU]/mL, , 10000.0 units/mL, 11700.0 units/mL, 160000.0 units/mL, 80000.0 units/mL, 120000.0 units/mL, 20000.0 units/mL
, Subcutaneous, Injection, solution, Injection, solution - Subcutaneous, Solution, Solution - Subcutaneous, Liquid, Liquid - Subcutaneous, Injection, Injection - Subcutaneous

Warnings

Innohep has five contraindications, thus it should not be combined with the circumstances featured in the following table.Innohep Contraindications
Condition
Risk Level
Notes
history of thrombocytopenia caused by Heparin
Do Not Combine
Pulse Frequency
Do Not Combine
Thrombocytopenia caused by Heparin
Do Not Combine
Hemorrhage
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Innohep.
Common Innohep Drug Interactions
Drug Name
Risk Level
Description
Albutrepenonacog alfa
Major
The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Tinzaparin.
Andexanet alfa
Major
The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Tinzaparin.
Anti-inhibitor coagulant complex
Major
The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Tinzaparin.
Antihemophilic factor (recombinant), PEGylated
Major
The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Tinzaparin.
Antihemophilic factor human
Major
The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Tinzaparin.
Innohep Toxicity & Overdose RiskTaking LMWH for an extended period of time can lead to osteoporosis, bleeding, hair loss, and HIT. Tinzaparin has been shown to be safe and not cause any toxic effects in mice, rats, and dogs even at doses up to 5mg/kg.
image of a doctor in a lab doing drug, clinical research

Innohep Novel Uses: Which Conditions Have a Clinical Trial Featuring Innohep?

48 active clinical trials are investigating the potential of Innohep to provide indwelling intravenous lines, prophylaxis of Clotting and Prophylaxis of Venous Thromboembolic Events for treatment of various conditions.
Condition
Clinical Trials
Trial Phases
Prophylaxis of Venous Thromboembolic Events
1 Actively Recruiting
Phase 1
Thrombosis
0 Actively Recruiting
indwelling intravenous lines
0 Actively Recruiting
Pulmonary Embolism
0 Actively Recruiting
Orthopedic Procedures
1 Actively Recruiting
Phase 4
prophylaxis of Clotting
0 Actively Recruiting
Deep Vein Thrombosis (DVT)
32 Actively Recruiting
Phase 4, Not Applicable, Early Phase 1, Phase 3, Phase 2, Phase 1
General Surgery
2 Actively Recruiting
Not Applicable
Deep Vein Thrombosis
10 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 4

Innohep Reviews: What are patients saying about Innohep?

4Patient Review
12/12/2009
Innohep for Blood Clot in a Deep Vein
2.7Patient Review
1/29/2014
Innohep for Blood Clots in Deep Veins and in Blood Vessel of the Lung
I was disappointed that this didn't work more quickly. The swelling in my arm, forearm, and hand went down gradually over the course of three weeks. It has been effective in preventing another clot from occurring, though.
2.7Patient Review
5/18/2014
Innohep for Blood Clot in a Deep Vein
The daily shots are a bit of a pain, but they're nothing compared to the side effects of Xarelto.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about innohep

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is innohep the same as heparin?

"INNOHEP® (tinzaparin) and other low molecular weight heparins differ in manufacturing process, molecular weight distribution, anti-Xa and anti-IIa activities, units, and dosage, so they cannot be used interchangeably (unit for unit). Each of these medications has its own instructions for use."

Answered by AI

Where do you inject innohep when pregnant?

"It is safe to inject LMWH into the abdomen, upper outer side of the thigh, or upper outer part of the buttock while pregnant. If you have had surgery (such as a caesarean section), avoid injecting too close to the wound or bandages."

Answered by AI

What is innohep used for?

"Innohep prevents clotting and allows normal blood flow through the arteries and veins. It is used to prevent blood clots in adults before and after an operation, or in those who have an increased risk of developing them due to an acute illness or limited mobility."

Answered by AI

How is innohep given?

"The medication should be injected into the skin of the stomach or abdomen, as directed by a doctor. It is usually injected once per day. Do not inject it into a muscle. The dosage and length of treatment depend on the person's medical condition, weight, and response to treatment. It is important to use this medication regularly to get the most benefit from it."

Answered by AI

Clinical Trials for Innohep

Image of St.Joseph's Healthcare Hamilton in Hamilton, Canada.

Rivaroxaban + ASA for Hip Fracture

18+
All Sexes
Hamilton, Canada
A third of patients undergoing surgery for a hip fracture develop a myocardial injury (i.e., an elevated troponin measurement), and these patients are at substantial risk of death and morbidity. Current prophylaxis strategies focus on preventing venous thromboembolism (VTE); however, arterial events are more common and carry a poor prognosis. The association of acetylsalicylic acid (ASA) 75-100 mg once daily and rivaroxaban 2.5 mg twice a day (the regimen used in the COMPASS trial) might prevent both VTE and arterial cardiovascular events. Among patients who have undergone hip fracture surgery and have evidence of myocardial injury, to explore the feasibility of a randomized controlled trial (RCT) comparing rivaroxaban 2.5 mg twice daily + low-dose ASA (75-100 mg) for 90 days, with standard VTE thromboprophylaxis for 30 days, for prevention of major cardiovascular events. The HIPSTER-Pilot is a multicenter, international, open-label, pilot RCT with blinded outcome adjudication. A total of 100 participants aged ≥45 years who received hip fracture surgery and experienced a myocardial injury will be randomized to receive either rivaroxaban 2.5 mg twice daily plus ASA 75-100 mg daily for 90 days or standard VTE prophylaxis with an anticoagulant for 30 days. The primary feasibility outcome will be the recruitment rate. Other feasibility measures include completeness of follow-up and adherence to the treatment. Exploratory clinical outcomes will be assessed. This pilot trial will provide information on the feasibility of conducting a larger RCT to evaluate the efficacy and safety of the COMPASS regimen for preventing arterial and venous thrombotic events after hip fracture surgery in patients who have had myocardial injury. The results of this feasibility study will inform the design of the full-scale trial.
Phase 3
Waitlist Available
St.Joseph's Healthcare Hamilton (+1 Sites)Federico Germini, Doctor of Medicine
Image of SUNY Upstate in Syracuse, United States.

Apixaban or Enoxaparin for Head and Neck Cancer Surgery

18 - 89
All Sexes
Syracuse, NY
The goal of this clinical trial is to learn if apixaban (a pill) is a safe and easier alternative to taking enoxaparin (a daily shot) to prevent blood clots after head and neck cancer surgery. It will also learn about side effects of both medicines. The main questions it aims to answer are: Can apixaban be used safely instead of enoxaparin to prevent blood clots after surgery? Do patients find apixaban easier or more satisfying to take than enoxaparin? How well do patients follow the treatment plan with each medicine? Researchers will compare 2 groups: One group will take apixaban (a pill taken twice a day) for 10 days after surgery. The other group will take enoxaparin (a shot given once a day) for 10 days after surgery. Participants will: Take either apixaban or enoxaparin starting 12-24 hours after surgery, for 10 days total Keep a medication diary and bring back unused medicine so the study team can check adherence Complete short surveys about satisfaction with their medicine Have an ultrasound of their legs to check for blood clots 11-14 days after surgery Return for follow-up visits about 40 days and 80 days after surgery for safety checks How long will participation last? About 4 months from surgery through the last follow-up visit.
Phase 4
Recruiting
SUNY Upstate
Image of Denver Metro Orthopedics, P.C. Englewood Location in Englewood, United States.

REGN7508 for Venous Thromboembolism

18+
All Sexes
Englewood, CO
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing venous thromboembolism (VTE) and other related diseases after total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Phase 3
Recruiting
Denver Metro Orthopedics, P.C. Englewood Location (+6 Sites)Clinical Trial ManagementRegeneron Pharmaceuticals
Image of University of Vermont Medical Center in Burlington, United States.

Apixaban for Cancer

18+
All Sexes
Burlington, VT
Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death. Although national guidelines recommend using blood thinners (anticoagulants) to prevent clots in cancer patients who are at higher risk, these medications are not commonly prescribed due to concerns about bleeding and inconvenience. This study will test different ways of using a commonly prescribed blood thinner called apixaban (brand name Eliquis) to see if it can safely and effectively reduce the risk of blood clots and death in cancer patients who are at moderate risk for VTE. The study focuses on people who have a "Khorana score" of 2, which puts them at intermediate risk for developing blood clots. The study will include approximately 996 participants with solid tumors or lymphoma who are starting or recently started cancer-directed therapy. Participants will be randomly assigned to one of three groups: Group 1: Apixaban 2.5 mg twice a day (standard prophylactic dose) Group 2: Apixaban 5 mg once a day (an alternative, more convenient dose) Group 3: No anticoagulant (standard care) Participants will take the assigned treatment (if applicable) for 6 months. Researchers will monitor whether participants develop blood clots, experience serious bleeding events, or die from any cause during the study period. By comparing these three groups, the researchers hope to learn whether a once-daily dose of apixaban can work as well as the standard twice-daily dose, and whether either dosing strategy is better than no anticoagulation at all. If successful, the study may help increase the safe use of VTE prevention in cancer patients and improve overall outcomes, especially in patients at intermediate risk. This is a pragmatic trial, meaning it is designed to fit into real-world clinical practice with minimal extra procedures. The study drug is not provided by the sponsor and will be prescribed and filled through usual care channels. Participants and their doctors will decide whether to continue the medication after the study ends.
Phase 3
Waitlist Available
University of Vermont Medical Center
Have you considered Innohep clinical trials? We made a collection of clinical trials featuring Innohep, we think they might fit your search criteria.Go to Trials
Have you considered Innohep clinical trials? We made a collection of clinical trials featuring Innohep, we think they might fit your search criteria.Go to Trials
Image of RUSH University Medical Center in Chicago, United States.

Thrombolysis/Thrombectomy for Deep Vein Thrombosis

18 - 75
All Sexes
Chicago, IL
The goal of this study is to fill the paucity of second line endovascular treatment for acute deep venous thrombus (DVT) by using catheter-directed thrombolysis (CDT) and mechanical thrombectomy (MT) as adjunctive second-line treatments for acute DVT patients who show no improvement after an initial anticoagulation trial for one week. The main questions the study aims to answer are: \- Are adjunctive use of endovascular interventional treatments as second-line to DVT treatment safe and efficient? Participants will be followed with repeat US at 1 week after initial DVT to assess for response to anticoagulation treatment. If there is significant residual thrombus with minimal or no response to treatment, participants will be offered enrollment to the study in the office or inpatient setting. Enrolled participants will be randomized into control or intervention arms with 1:1 ratio. Researchers will compare follow-up Villalta and Marder scores between groups to see whether endovascular interventions are safe and efficient.
Phase 4
Waitlist Available
RUSH University Medical CenterBulent Arslan, MD
Image of Medical University of South Carolina in Charleston, United States.

Education + Decision Support for Blood Clots After Cancer Surgery

18+
All Sexes
Charleston, SC
While blood clots after major cancer surgery are common and harmful to patients, the medications to decrease blood clot risk are seldom used after patients leave the hospital despite the recommendation of multiple professional medical societies. The reason why these medications are seldom prescribed is not well understood. The main questions this study aims to answer are: * Does surgeon education paired with an electronic medical record based decision support tool improve the guideline concordant prescription of pharmacologic venous thromboembolism after abdominopelvic cancer surgery? * Does dedicated patient education regarding blood clots at the time of hospital discharge after abdominopelvic cancer surgery improve understanding of the risk of venous thromboembolism and adherence to pharmacologic prophylaxis? The investigators will study these questions using a stepped-wedge randomized trial where groups of surgeons will use a tool integrated to the electronic medical record to educate them on the individualized patient risks of blood clots after major cancer surgery and inform them regarding guidelines for preventative medicines. Utilization of the medications before and after using the tool will be compared. Patients will be administered a questionnaire assessing their awareness of blood clots as a risk after cancer surgery. For those prescribed medications to reduce blood clot risk after leaving the hospital, the questionnaire will evaluate whether they took the medications as prescribed. Survey results will be evaluated before and after implementation of education on blood clot risk at the time of hospital discharge.
Recruiting
Has No Placebo
Medical University of South CarolinaThomas Curran, MD MPH
Have you considered Innohep clinical trials? We made a collection of clinical trials featuring Innohep, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security